LGALS3 and acute lymphoblastic leukemia: We recently showed that B-cell precursor acute lymphoblastic leukemia (pre-B ALL) cells derived from galectin3−/− mice are more sensitive to drug treatment than wild type cells, and that overexpression of Galectin-3 by retroviral transduction protects pre-B ALL cells against drug treatment [6].